Comparing Legflow DCB to standard balloon treatment for leg artery issues

SIGNATURE Study: Post-market, Randomized Controlled, Multicenter, Single Blinded Prospective Trial Investigating the Paclitaxel-Coated Balloon (Legflow DCB) Treatment Versus Uncoated Balloon Angioplasty Treatment for Femoro-popliteal Lesions.

This study is testing if a new drug-coated balloon treatment for leg artery problems can work better and be safer than the standard balloon treatment for people with peripheral artery disease.

Quick facts

• Study type: Observational
• Enrollment: 148 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Cardionovum GmbH (industry)
• Locations: 6 sites (Berlin and 5 other locations)
• Trial ID: NCT04971772 on ClinicalTrials.gov

What this trial studies

This observational study aims to compare the safety and efficacy of the Legflow drug-coated balloon (DCB) against standard plain old balloon angioplasty (POBA) in patients suffering from symptomatic peripheral artery disease (PAD) due to stenosis or occlusion in the femoral and popliteal arteries. Patients aged 18 and older with specific criteria related to their arterial lesions will be enrolled. The study will assess the outcomes of these two treatment approaches to determine if the Legflow DCB offers superior results. Participants will be monitored for safety and effectiveness following their treatment.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with specific types of stenotic or occlusive lesions in their leg arteries.

Not a fit: Patients with lesions that do not meet the specified criteria or those with other significant health issues may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a more effective treatment option for patients with peripheral artery disease, potentially improving their quality of life.

How similar studies have performed: Previous studies have shown promising results with drug-coated balloons in treating peripheral artery disease, suggesting that this approach may be effective.

Eligibility criteria

Inclusion criteria

* Patient is ≥18 years
* Patient has Rutherford Classification 2,3 or4.
* Patient has provided written informed consent and is willing to comply with study follow-up requirements.
* De novo stenotic or occlusive lesion(s) or non-stented restenotic or occlusive lesion(s) occurring \>90 days after prior plain old balloon (POBA) angioplasty or \>180 days after prior DCB treatment.
* Target lesion is located between the ostium of the SFA and the end of the P1 segment of the popliteal artery
* Target vessel diameter ≥ 4 mm and ≤ 7 mm
* Target lesion must be stenotic or occlusive lesion ≤ 150mm in length (one long lesion or tandem lesions) by investigator's visual estimate. \[Note: tandem lesions must have a total length of ≤ 150 mm by visual estimate and be separated by ≤ 30 mm.\]
* Target lesion must have angiographic evidence of ≥ 70 % stenosis by investigator's visual estimation
* Successful, uncomplicated crossing of the target lesion occurs when the tip of the guidewire is distal to the target lesion without the occurrence of flow-limiting dissection of perforation and is judged by visual inspection to be within the true lumen. Subintimal dissection techniques may be used if re-entry occurs above-the-knee (ATK) and without the use of re-entry devices.
* Target lesion is located at least 30mm from any stent if target vessel was previously stented.
* A patent inflow artery free from significant stenosis ((≥50% stenosis) as confirmed by angiography.
* At least one patent native outflow artery to the ankle or foot, free from significant stenosis (≥ 50 % stenosis) as confirmed by angiography.

Exclusion criteria:

* Acute Limb Ischemia
* Patient underwent an intervention involving the target vessel within the previous 90 days.
* Patient underwent any lower extremity percutaneous treatment in the ipsilateral limb using plain old balloon (POBA) angioplasty within the previous 90 days.
* Patient underwent a percutaneous transluminal angioplasty (PTA) of the target lesion using a DCB within the previous 180 days.
* Pregnant women or women who are intending to become pregnant.
* Patient has a life expectancy of less than 1 year
* Patient has a known allergy to contrast medium that cannot be adequately pre-medicated.
* Patient is allergic to all anti-platelet treatments
* Patient is receiving immunosuppressant therapy
* Patient has platelet count \<100.000/mm3 or \>700.000/mm
* Patient has history of gastrointestinal hemorrhage requiring a transfusion within 3 months prior to the study procedure
* Patient is diagnosed with coagulopathy that precludes treatment with systemic anticoagulation and/or dual antiplatelet therapy (DAPT)
* Patient has history of stroke within past 90 days
* Patient has history of myocardial infarction within the past 30 days.
* Patient is participating in an investigational drug or medical device study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints from this study.
* Patient has had any major (e.g. cardiac, peripheral, abdominal) surgical procedure or intervention unrelated to this study within 30 days prior to the index procedure or has planned major surgical procedure or intervention within 30 days of the index procedure
* An intervention in the contralateral limb, planned within 30 days post-index procedure
* Patient had previous bypass surgery of the target lesion
* Patient had previous treatment of the target vessel with thrombolysis or surgery
* Patient is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol
* Target lesion involves an aneurysm or is adjacent to an aneurysm (within 5 mm)
* Target Lesion requires treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy or re-entry devices
* Significant target vessel tortuosity or other parameters prohibiting access to the target lesion
* Presence of thrombus in the target vessel
* Iliac inflow disease requiring treatment, unless the iliac artery disease is successfully treated first during the index procedure. Success is defined as ≤ 30 % residual diameter stenosis without death or major complications.
* Presence of an aortic, iliac or femoral artificial graft.

Where this trial is running

Berlin and 5 other locations

• Sankt Gertrauden-Krankenhaus Berlin — Berlin, Germany (RECRUITING)
• Medizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer GmbH — Hamburg, Germany (RECRUITING)
• Universitätsklinikum Heidelberg — Heidelberg, Germany (RECRUITING)
• SRH Klinikum Karlsbad-Langenseinbach GmbH — Karlsbad, Germany (RECRUITING)
• St. Franziskus-Hospital GmbH — Münster, Germany (RECRUITING)
• GRN-Klinik Weinheim — Weinheim, Germany (RECRUITING)

Study contacts

• Study coordinator: Sabrina Overhagen, Dr.

Conditions: Peripheral Arterial Disease, Superficial Femoral Artery Stenosis, Angiopathy, Peripheral